Surface Plasmon Resonance (SPR) Biosensor- Biacore T200

描述(由申请人提供)：范斯坦医学研究所是一个不断发展的非营利性研究中心，隶属于纽约长岛的North Shore-LIJ卫生系统。该研究所的研究人员在上一财年获得了约4670万NIH的资助，使其成为纽约大都市区的主要研究机构之一。范斯坦研究所的大部分研究高度集中在临床疾病以及自身免疫性、炎症性和神经退行性疾病的创新治疗策略和新疗法的开发上。 Biacore T200表面等离子体共振生物传感器对于该研究所来说将是一个特别重要的补充，该研究所明确地将重点放在翻译研究和新的疗法上。该研究所拥有一个药物化学实验室，由优素福·阿贝德博士管理。药物化学实验室与几名研究人员合作，识别具有诊断或激动剂/拮抗剂特性的小分子，针对人类疾病重要途径中的高度特定目标。目前，拟议的表面等离子体共振(SPR)项目包括寻找针对类风湿性关节炎、系统性红斑狼疮、阿尔茨海默病、败血症和癌症靶点的先导化合物。在化合物筛选过程中对结合亲和力和动力学(KD‘s和KD’s)的分析将使这些药物发现工作最优化。其他研究人员希望使用该仪器来研究抗体对DNA或蛋白质的亲和力，以及蛋白质/蛋白质的相互作用。 这项技术允许对结合进行高度定量的分析，并有可能回收新的结合蛋白用于随后的鉴定和表征，扩展了诸如ELISA、荧光偏振和酵母双杂交系统等技术。该系统的微型和自动化设置也使其具有极大的通用性。 我们相信，获得这项技术将促进研究所众多科学家的研究，并使他们能够在分析开发和故障排除、时间管理和成本效益方面以更熟练的方式工作。 公共卫生相关性：范斯坦医学研究所的一个主要重点是将基础科学的发现转化为人类疾病的新疗法。Biacore T200生物传感器是一种仪器，将有助于促进对人类疾病中重要的分子相互作用的了解，并筛选可能使这些相互作用痛苦或拮抗的治疗化合物。该研究所引以为豪的是，它发现了新的疾病靶标，这些靶标要么来自于临床研究，要么源于临床研究，并开发了创新的诊断、治疗和治疗方法，有朝一日可能有助于减轻人类疾病。

DESCRIPTION (provided by applicant): The Feinstein Institute for Medical Research is a growing non-profit research center affiliated with the North Shore-LIJ Health System in Long Island, NY. Investigators at the Institute received approximately 46.7 million in the last fiscal year in NIH funding, making it among one of the major research facilities in the New York metropolitan area. Much of the research at the Feinstein is highly focused on clinical disease and the development of innovative therapeutic strategies and novel therapeutics in autoimmune, inflammatory, and neurodegenerative disease. The Biacore T200 surface plasmon resonance biosensor would be an especially important addition for the Institute which has a clear focus on translational studies and novel therapeutics. The Institute boasts a Laboratory of Medicinal Chemistry, run by Dr. Yousef Al-Abed. The Medicinal Chemistry laboratory works with several investigators to identify small molecules with diagnostic or agonist/antagonist properties directed to highly specific targets in pathways of importance in human disease. Currently, proposed surface plasmon resonance (SPR) projects include searching for lead compounds to targets in rheumatoid arthritis, systemic lupus erythematosus, Alzheimer's disease, sepsis and cancer. Analysis of binding affinities and kinetics (KD's and Kd's) during compound screening will allow optimization of these drug discovery efforts. Other investigators hope to use the instrument to study antibody affinity to DNA or protein, and protein/protein interactions. This technology allows for highly quantitative analysis of binding along with the possibility to recover novel binding proteins for subsequent identification and characterization, extending techniques such as ELISA, fluorescence polarization, and yeast two-hybrid systems. The micro-scale and automated set-up of the system also makes it extremely versatile. We are confident that acquisition of this technology will facilitate the research of numerous scientists at the Institute and allow them to work in a more proficient manner in terms of assay development and troubleshooting, time management, and cost- effectiveness. Public Health Relevance: A major focus of the Feinstein Institute for Medical Research is to translate discoveries in the basic sciences into new therapies for human disease. The Biacore T200 biosensor is an instrument that will serve to advance the understanding of molecular interactions important in human disease and also to screen therapeutic compounds which may agonize or antagonize those interactions. The Institute prides itself in the discovery of novel disease targets, originating either on the bench or from clinical research, and the development of innovative diagnostics, treatments and therapies which may one day help to alleviate human disease.